BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• Business

  Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

  Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced financial results and provided a corporate update for the first quarter ended March 31, 2023.

  May 9, 2023

   · 

  12 min read
• Business

  Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

  Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, provided a corporate update and reported first quarter 2023 financial results.

  May 9, 2023

   · 

  9 min read
• Business

  Seer Reports First Quarter 2023 Financial Results

  Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the first quarter ended March 31, 2023.

  May 9, 2023

   · 

  7 min read
• Business

  Cytek Biosciences Reports First Quarter 2023 Financial Results

  Cytek® Biosciences, Inc. reported financial results for the first quarter ended March 31, 2023.

  May 9, 2023

   · 

  16 min read
• Business

  Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported financial results for the first quarter of 2023.

  May 9, 2023

   · 

  12 min read
• Business

  Supernus Announces First Quarter 2023 Financial Results

  Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced financial results for the first quarter of 2023, and associated Company developments.

  May 9, 2023

   · 

  14 min read
• Business

  Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

  May 9, 2023

   · 

  12 min read
• Business

  Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

  Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported financial results for the quarter ended March 31, 2023, and provided a business update.

  May 9, 2023

   · 

  10 min read
• Drug Development

  Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

  Ardelyx, Inc. (Nasdaq: ARDX) today announced that a new analysis from IBSRELA Phase 3 trial, T3MPO-2, was presented in a poster presentation at the 2023 Digestive Disease Week Conference (DDW 2023) that is now underway in Chicago, Illinois.

  May 9, 2023

   · 

  6 min read
• Business

  Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

  Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

  May 9, 2023

   · 

  9 min read